American Home Products Corp., New York, said unit Wyeth-Ayerst Laboratories agreed to invest a minimum of $57 million in a major drug discovery program at Affymax NV, a Netherlands-based pharmaceuticals company.
In return, Wyeth-Ayerst receives world-wide rights to potential pharmaceutical products developed under the collaboration.
The news drove up Affymax's shares, which closed at $18, up $1.75, or 11%, in Nasdaq Stock Market trading.
Under terms of the agreement, WyethAyerst will invest $47 million in research and development payments over five years and purchase $10 million of Affymax's shares at $20 a share.
The agreement includes options by Wyeth-Ayerst to extend the collaboration for up to two additional two-year periods, including additional equity and research and development payments.
